Data as of Apr 17
| +0.0201 / +2.09%|
The 3 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 2.50. The median estimate represents a +206.12% increase from the last price of 0.98.
The current consensus among 3 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.